Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.

Authors:
Zheng H; Li H; Wang Y; Li Z; Hu B and 12 more

Journal:
Stroke

Publication Year: 2022

DOI:
10.1161/STROKEAHA.120.031877

PMCID:
PMC9508961

PMID:
36017704

Journal Information

Full Title: Stroke

Abbreviation: Stroke

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosures Michiel L. Bots declares no conflicts of interest, apart from being paid for his services by the organization that received the METEOR-China grant from AstraZeneca to run the study. The payment went to UMC Utrecht. Drs Karlson, Zhao, Wei, and Meng are employees of AstraZeneca. The other authors report no conflicts."

Evidence found in paper:

"Sources of Funding The METEOR-China study was funded by AstraZeneca. AstraZeneca was involved in study design, conduct, and data management and analysis. AstraZeneca was given an opportunity to review the article for scientific accuracy."

Evidence found in paper:

"Registration:: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02546323."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025